SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-17-004936
Filing Date
2017-05-04
Accepted
2017-05-04 16:18:25
Documents
55
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20170331x10q.htm 10-Q 683982
2 EXHIBIT 10.1 miratiamendedandrestatedno.htm EX-10.1 22826
3 EXHIBIT 31.1 mrtx33117ex311.htm EX-31.1 12403
4 EXHIBIT 31.2 mrtx33117ex312.htm EX-31.2 12867
5 EXHIBIT 32.1 mrtx33117ex321.htm EX-32.1 8228
  Complete submission text file 0001628280-17-004936.txt   3143550

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT mrtx-20170331.xml EX-101.INS 605541
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20170331.xsd EX-101.SCH 24443
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20170331_cal.xml EX-101.CAL 45737
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20170331_def.xml EX-101.DEF 81451
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20170331_lab.xml EX-101.LAB 306908
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20170331_pre.xml EX-101.PRE 170534
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 17814191
SIC: 2834 Pharmaceutical Preparations